Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Stock Chart & Stats
$3.98
-$0.14(-4.27%)
At close: 4:00 PM EST
$3.98
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.11 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)3.49M
Market Cap
$718.43M
Enterprise Value$794.04M
Total Cash (Recent Filing)$208.43M
Total Debt (Recent Filing)$118.14M
Price to Earnings (P/E)―
Beta3.03
Next Earnings
Feb 27, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding180,510,650
10 Day Avg. Volume3,694,444
30 Day Avg. Volume3,487,480
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.26
Price to Sales (P/S)116.10
P/FCF Ratio-2.66
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue132.85
Enterprise Value/Gross Profit-19.91
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$6.06Price Target Upside52.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$18.22M
Bulls Say, Bears Say
Bulls Say
Mutation-agnostic PlatformPrime Medicine's mutation-agnostic prime editing approach can address a broad range of patient mutations, expanding the addressable population for Wilson's disease and AATD compared with mutation-specific therapies.
Preclinical Efficacy And DurabilityRobust preclinical data showing high editing efficiency and durable genetic correction in animal models support PM577's potential as a one-time curative therapy for Wilson's disease.
Safety Profile Versus Standard Of CarePM577's editing mechanism may avoid the neurotoxicity linked to copper chelators, positioning the therapy as a safer alternative that could improve patient outcomes and uptake.
Bears Say
Financial Runway And Funding RiskRecent quarterly operating losses and the company's cash balance highlight potential funding pressure and the risk of future dilution if clinical development timelines lengthen.
Investor Sentiment And Short InterestA high short interest as a percentage of float signals notable investor skepticism and could increase downside pressure on the stock if development risks materialize.
Reimbursement And Pricing RiskThe existing high cost burden of Wilson's disease treatments may prompt intense payer scrutiny and create reimbursement challenges for a novel gene-editing therapy.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $718.43M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Feb 27, 2026 which is in 39 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Nov 07, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.253 by -$0.067.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,510,650 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.253. Following the earnings report the stock price went down -8.852%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.06 (52.26% Upside)
$6.06 (52.26% Upside)
Blogger Sentiment
Neutral
PRME Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 13.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.67%
12-Months-Change
Fundamentals
Return on Equity
-112.34%
Trailing 12-Months
Asset Growth
15.69%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$6.06
▲(52.26% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---